Search results
Added:
1 month ago
Lipid-lowering Therapies and Lp(a)
Added:
2 weeks ago
Review Article
Added:
1 year ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising…
View more
Added:
1 month ago
Added:
5 months ago
Added:
2 months ago
Source:
Radcliffe CVRM
For patients with heterozygous familial hypercholesterolemia (HeFH), achieving adequate low-density lipoprotein cholesterol (LDL-C) lowering remains a significant challenge. New results from the BROOKLYN trial suggest that the investigational agent obicetrapib could be an effective add-on therapy for this high-risk population.¹Mechanism of ActionObicetrapib is a highly selective cholesteryl ester…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an…
View more
Advancements in Triglyceride-lowering Therapies
Video Series
Added:
2 weeks ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc analysis of the SURPASS-CVOT trial suggests that tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a lower incidence of a broad composite of cardiorenal events compared with the GLP-1 receptor agonist dulaglutide in patients with type 2 diabetes and established cardiovascular disease.¹Tirzepatide is a dual agonist that targets both…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England…
View more